Tag
A new Nature study led by Monash University's Devon Stoliker challenges the idea that psychedelics simply create chaos in the brain, using AI analysis of MRI and EEG scans from psilocybin sessions to reveal structured changes in brain network connectivity that may underlie meaningful, insightful experiences.
Eli Lilly has acquired AtaiBeckley, a psychedelics biotech company founded by Christian Angermayer, for up to $3.8 billion, marking the largest transaction in the psychedelic sector.
A large neuroimaging study published in Nature found that psilocybin creates hidden order in brain activity, making neural signals clearer during psychedelic experiences, which could enhance psychedelic therapy by emphasizing context and environment.
Early clinical trial results suggest psilocybin, the active ingredient in magic mushrooms, could kick-start recovery in anorexia patients, offering a potential new treatment for a disorder with high mortality and limited effective therapies.
An article exploring the use of drugs like ketamine and psychedelics by AI industry workers, referencing Elon Musk and Peter Thiel, and questioning potential impacts on AI models.
This case report documents transient multidomain functional improvements in an advanced Alzheimer's patient following high-dose psilocybin administration, with recovery of speech, continence, and social interaction over days to weeks.